Cargando…

Comparison of long‐term use of prolonged‐release ropinirole and immediate‐release dopamine agonists in an observational study in patients with Parkinson's disease

PURPOSE: To estimate the risk of dyskinesia and impulse control disorders (ICDs) in patients with Parkinson's disease (PD) prescribed ropinirole prolonged‐release (R‐PR) compared to those prescribed immediate‐release dopamine agonists (IR‐DA) as monotherapy. METHODS: PD patients initiating R‐PR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gungabissoon, Usha, Kirichek, Oksana, El Baou, Céline, Galwey, Nicholas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Original Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317950/ https://www.ncbi.nlm.nih.gov/pubmed/32153056 http://dx.doi.org/10.1002/pds.4986

Ejemplares similares

A review of ropinirole prolonged release in Parkinson’s disease
por: Nashatizadeh, Muhammad M, et al.
Publicado: (2009)

Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson’s disease
por: Yun, Ji Young, et al.
Publicado: (2013)

Sleep Duration and “on” Time during Different Periods of the Day and Night in Patients with Advanced Parkinson's Disease Receiving Adjunctive Ropinirole Prolonged Release
por: Reichmann, Heinz, et al.
Publicado: (2011)

Clinical Observation of Ropinirole Hydrochloride in the Treatment of Parkinson's Disease
por: Zhang, JingZhou, et al.
Publicado: (2022)

Retracted: Clinical Observation of Ropinirole Hydrochloride in the Treatment of Parkinson's Disease
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Update on ropinirole in the treatment of Parkinson’s disease
por: Shill, Holly A, et al.
Publicado: (2009)

The association between dementia severity and hospitalisation profile in a newly assessed clinical cohort: the South London and Maudsley case register
por: Gungabissoon, Usha, et al.
Publicado: (2020)

Potentially avoidable causes of hospitalisation in people with dementia: contemporaneous associations by stage of dementia in a South London clinical cohort
por: Gungabissoon, Usha, et al.
Publicado: (2022)

Influence of Selective Dopamine Agonist Ropinirole on Conditioned Place Preference and Somatic Signs of Morphine Withdrawal in Rats
por: Shahzadi, Andleeb, et al.
Publicado: (2022)

The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson’s disease: an observational study
por: Pellicano, Clelia, et al.
Publicado: (2013)

Feasibility of a randomized single-blind crossover trial to assess the effects of the second-generation slow-release dopamine agonists pramipexole and ropinirole on cued recall memory in idiopathic mild or moderate Parkinson’s disease without cognitive impairment
por: Shepherd, Thomas A., et al.
Publicado: (2017)

Impaired dopamine release in Parkinson’s disease
por: Cramb, Kaitlyn M L, et al.
Publicado: (2023)

Nanotechnology-based drug delivery of ropinirole for Parkinson’s disease
por: Barcia, Emilia, et al.
Publicado: (2017)

Sleepiness and Depression in Parkinson’s Disease Patients Treated with Ropinirole and Levodopa
por: Kang, Suk Yun, et al.
Publicado: (2017)

Bioavailability of Oniria(®), a Melatonin Prolonged-Release Formulation, Versus Immediate-Release Melatonin in Healthy Volunteers
por: Román Martinez, Manuel, et al.
Publicado: (2022)

Clinical evaluation of switching from immediate‐release to prolonged‐release lithium in bipolar patients, poorly tolerant to lithium immediate‐release treatment: A randomized clinical trial
por: Pelacchi, Federica, et al.
Publicado: (2022)

Ropinirole, a dopamine agonist with high D(3) affinity, reduces proactive inhibition: A double-blind, placebo-controlled study in healthy adults
por: Rawji, Vishal, et al.
Publicado: (2020)

Are Branded and Generic Extended-Release Ropinirole Formulations Equally Efficacious? A Rater-Blinded, Switch-Over, Multicenter Study
por: Bosnyák, Edit, et al.
Publicado: (2014)

Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease
por: Kim, Han-Joon, et al.
Publicado: (2011)

Ropinirole for the treatment of restless legs syndrome
por: Kushida, Clete A
Publicado: (2006)

Spectrophotometric Estimation of Ropinirole Hydrochloride in Tablets
por: Shete, Yogita, et al.
Publicado: (2009)

Treatment of Gait Ignition Failure with Ropinirole
por: Cohen-Oram, Alexis N., et al.
Publicado: (2014)

Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation
por: Del Bello, Arnaud, et al.
Publicado: (2021)

Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers
por: Ait Abdellah, Samira, et al.
Publicado: (2023)

The treatment of Parkinson's disease with dopamine agonists
por: Konta, Brigitte, et al.
Publicado: (2008)

The effect and safety of ropinirole in the treatment of Parkinson disease: A systematic review and meta-analysis
por: Zhu, Jiali, et al.
Publicado: (2021)

Plasticity in striatal dopamine release is governed by release-independent depression and the dopamine transporter
por: Condon, Mark D., et al.
Publicado: (2019)

Dissolution of Intact, Divided and Crushed Circadin Tablets: Prolonged vs. Immediate Release of Melatonin
por: Chua, Hui Ming, et al.
Publicado: (2016)

Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease
por: Shen, Zhengze, et al.
Publicado: (2018)

A Prospective, Observational Study of Conversion From Immediate- to Prolonged-Release Tacrolimus in Renal Transplant Recipients in France: The OPALE Study
por: Moal, Valérie, et al.
Publicado: (2019)

Dopamine Agonist Therapy in Advanced Parkinson’s Disease
por: Reichmann, Heinz
Publicado: (2009)

Comparison of D(2) dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects
por: Nord, Magdalena, et al.
Publicado: (2011)

A Multicenter, Prospective, Observational Study of Conversion from Twice-Daily Immediate-Release to Once-Daily Prolonged-Release Tacrolimus in Liver Transplant Recipients in France: The COBALT Study
por: Dumortier, Jérôme, et al.
Publicado: (2019)

Reduced striatal dopamine release during motor skill acquisition in Parkinson’s disease
por: Kawashima, Shoji, et al.
Publicado: (2018)

Quality Control Dissolution Data Is Biopredictive for a Modified Release Ropinirole Formulation: Virtual Experiment with the Use of Re-Developed and Verified PBPK Model
por: Shuklinova, Olha, et al.
Publicado: (2022)

Population pharmacokinetics of immediate‐ and prolonged‐release tacrolimus formulations in liver, kidney and heart transplant recipients
por: Lu, Zheng, et al.
Publicado: (2019)

Dopamine Dysregulation Syndrome in Parkinson’s Disease Patients with Unsatisfactory Switching from Immediate to Extended Release Pramipexole: A Further Clue to Incentive Sensitization Mechanisms?
por: Solla, Paolo, et al.
Publicado: (2013)

Single- and multiple-dose pharmacokinetics of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) compared with immediate-release hydrocodone bitartrate/ibuprofen and immediate-release tramadol HCl/acetaminophen
por: Devarakonda, Krishna, et al.
Publicado: (2015)

Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate‐ or prolonged‐release tacrolimus
por: Vondrak, Karel, et al.
Publicado: (2019)

Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence
por: Muduma, Gorden, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jq4igk576ngkd8nibtdatnk2lc